## American Thyroid Association (ATA) National Thyroid Cancer Workshop Frontiers in Thyroid Cancer: ATA Guidelines in Clinical Practice

July 11-12, 2008 Boston Park Plaza Hotel and Towers Boston, Massachusetts

	I	I <b>–</b> •.	I =	
Friday,	Session Moderators:	Faculty	Faculty	Session
July 11	Richard Kloos & Ernest Mazzaferri			Chair
7:45 am	Welcome and ATA Guideline Comments	David Cooper		
8:00 am –	Changing Demographics in Thyroid Cancer:	Ernest		
8:30 am	Impact on Management	Mazzaferri		
8:30 am -	Thyroid Nodules: Diagnostic & Therapeutic	Hossein		
9:00 am	Dilemmas	Gharib		
9:00 am –	Preoperative & Initial Surgical	Gerard		
9:30 am	Management of DTC: Extent of Thyroid and	Doherty		
	Lymph node Surgery	-		
9:30 am –	Postoperative I-131 Remnant Ablation &	Bryan		
10:00 am	therapy: Risk & Benefits, I-131 Dosimetry	Haugen		
	vs. Empiric Therapy			
10:00 am –	BREAK (outside main meeting room)			
10:30 am				
10:30 am –	New Paradigms and Problems in the	Martin		
11:00 am	Follow-up of DTC: US, Tg, and imaging	Schlumberger		
11:00 am –	Panel Discussion Initial Management	Gerard	Furio	David
12:00 noon	Low and high Risk Tumors	Doherty;	Pacini	Cooper
12.00 110011	Low and high kisk runiors	Stephanie	Pacifii	Coopei
		Lee		
12:00 noon	Meet the Professor Sessions based on Case	Lee		
	Studies with LUNCH			
– 1:00 pm		Cusan Mandal		
	MTP1: Neck US for Thyroid Nodules, DTC,	Susan Mandel		
	& Lymph Node Metastases			
	MTP2: DTC & MTC Molecular-Based	Matthew		
	therapy and clinical trials	Ringel		
	MTP3: Management of DTC Distant	R. Mike Tuttle		
	Metastases			
	MTP4: TSH Suppression During DTC	David Cooper		
	Follow-up			
	MTP5: Management of Low Risk DTC	Stephanie		
	Patients	Lee		
1:00 pm –	Debate: Which thyroid Nodules Should	Susan Mandel	Bryan	Richard
2:00 pm	Undergo FNA		Haugen	Kloos
2:00 pm –	Debate: Prophylactic Central Neck	Gerard	David	Ernest
3:00 pm	Dissection in PTC	Doherty	Steward	Mazzaferri
3:00 pm –	BREAK (in the Exhibit Hall)			
3:30 pm	, , , , , , , , , , , , , , , , , , ,			
3:30 pm –	Debate: Radioiodine Ablation for Low Risk	Ernest	R. Mike	Matthew
4:30 pm	PTC	Mazzaferri	Tuttle	Ringel
4:30 pm –	Panel Discussion Case Management	Jeffrey	Matthew	Steven
5:30 pm	Distant Metastases	Moley; Martin	Ringel	Sherman
p		Schlumberger		
5:30 pm –	Questions & Answers	Bryan		
6:00 pm	ewostons & Answers	Haugen		
6:00 pm	Adjourn	ilaagon		
ο.οο μπ	Aujuuiii	1	]	]

Saturday,	Session Moderators:	Faculty	Faculty	Session
July 12	Richard Kloos & Ernest Mazzaferri	racuity	racuity	Chair
7:45 am	Welcome and ATA Guideline Comments	Richard Kloos		Citali
8:00 am –	Anaplastic Thyroid Cancer	Steven		
8:30 am	Anapiastic myroid cancer	Sherman		
8:30 am –	Panel: Observation vs Resection of	Jeffrey	Douglas	David
9:30 am	Persistent DTC lymph Node Metastases	Moley; Martin Schlumberger	Evans; Hossein Gharib	Steward
9:30 am –	Special Problems: Managing DTC during	Steven		
10:00 am	Pregnancy and in the Elderly Patients.	Sherman		
10:00 am – 10:30 am	BREAK (in the Exhibit Hall)			
10:30 am -	Panel: High Serum Tg levels and Negative	David	Furio	Bryan
11:30 am	Whole Body Scans	Steward; Hossein Gharib	Pacini	Haugen
11:30 am – 12:00 Noon	When to stop treating with radioiodine	R. Mike Tuttle		
12:00 noon	Meet the Professor Sessions based on Case			
– 1:00 pm	Studies with LUNCH			
	MTP1: Neck US for thyroid Nodules, DTC, & Lymph Node Metastases	Susan Mandel		
	MTP2: DTC & MTC Molecular-Based	Steven		
	Therapy and Clinical Trials	Sherman		
	MTP3: Management of DTC Distant Metastases	R. Mike Tuttle		
	MTP4: TSH Suppression During DTC	David Cooper		
	Follow-up	•		
	MTP5: Management of Low Risk DTC	Stephanie		
	Patients	Lee		
1:00 pm –	MTC Genotype-Phenotype Correlations and	Richard Kloos		
1:30 pm	Their Natural History			
1:30 pm –	Prophylactic Surgery for Medullary Thyroid	Douglas		
2:00 pm	Cancer: Timing & Outcome	Evans		
2:00 pm –	Therapeutic Surgery for MTC: pre-	Jeffrey Moley		
2:30 pm	operative evaluation and extent of surgery			
2:30 pm –	Persistent & Recurrent MTC: Evaluation	Martin		
3:00 pm	and Clinical Decision Making	Schlumberger		
3:00 pm –	BREAK (in the Exhibit Hall)			
3:30 pm				
3:30 pm - 4:00 pm	Targeting MTC for Molecular-Based Therapy: An Overview of Phase I and II	Samuel Wells		
4.00	Trials	Douglas		+
4:00 pm –	MEN 2 Associated Pheochromocytoma and	Douglas Evans		
4:30 pm	Hyperparathyroidism  Panel Discussion Case Management of MTC	Samuel	Dougles	Furio
4:30 pm – 5:30 pm	Panel Discussion Case Management of MTC	Wells;	Douglas Evans	Pacini
5.30 pm		Hossein	Evalis	Facilii
		Gharib		
5:30 pm –	Questions & Answers	Samuel Wells		1
6:00 pm				
6:00 pm	Adjourn			
		•	•	•